The UK will enter into a $624 million agreement to supply 60 million doses of potential COVID-19 vaccine from Sanofi and GlaxoSmithKline. Clinical trials of the vaccine are due to begin in September and full approval is expected by the first half of next year. Sanofi is capable of producing up to 1 billion doses per year. The supply agreement with Sanofi and GSK will be the second such deal for the UK, it was previously announced that the country will buy 100 million doses of AstraZeneca vaccine.
The UK will enter into a $624 million agreement to supply 60 million doses of potential COVID-19 vaccine from Sanofi and GlaxoSmithKline. Clinical trials of the vaccine are due to begin in September and full approval is expected by the first half of next year. Sanofi is capable of producing up to 1 billion doses per year. The supply agreement with Sanofi and GSK will be the second such deal for the UK, it was previously announced that the country will buy 100 million doses of AstraZeneca vaccine. 
uk.reuters.com
English (US) 